Perceptive Advisors LLC Purchases 300,000 Shares of Roivant Sciences Ltd. $ROIV

Perceptive Advisors LLC lifted its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 3.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,285,461 shares of the company’s stock after purchasing an additional 300,000 shares during the quarter. Roivant Sciences comprises about 4.5% of Perceptive Advisors LLC’s holdings, making the stock its 4th biggest holding. Perceptive Advisors LLC’s holdings in Roivant Sciences were worth $229,507,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Morgan Stanley raised its stake in Roivant Sciences by 31.7% during the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after purchasing an additional 14,036,696 shares during the period. Vanguard Group Inc. increased its holdings in shares of Roivant Sciences by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock worth $912,681,000 after buying an additional 3,254,113 shares during the last quarter. Rubric Capital Management LP increased its holdings in shares of Roivant Sciences by 14.7% during the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after buying an additional 2,603,260 shares during the last quarter. State Street Corp raised its position in shares of Roivant Sciences by 4.8% during the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock valued at $222,847,000 after buying an additional 911,827 shares during the period. Finally, UBS Group AG raised its position in shares of Roivant Sciences by 570.0% during the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after buying an additional 15,645,836 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, Director Daniel Allen Gold sold 12,380 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total transaction of $436,766.40. Following the transaction, the director directly owned 13,689,166 shares in the company, valued at $482,953,776.48. This represents a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction on Monday, July 27th. The stock was sold at an average price of $34.95, for a total value of $6,990,000.00. Following the transaction, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at approximately $56,376,551.85. This represents a 11.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 2,055,913 shares of company stock worth $69,639,633. Insiders own 10.80% of the company’s stock.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $33.91 on Friday. The firm’s 50 day moving average price is $32.63 and its 200-day moving average price is $29.05. Roivant Sciences Ltd. has a one year low of $10.90 and a one year high of $37.00. The firm has a market cap of $24.39 billion, a P/E ratio of -56.52 and a beta of 1.11.

Analyst Ratings Changes

A number of research analysts recently commented on ROIV shares. HC Wainwright reiterated a “buy” rating and issued a $34.00 price objective on shares of Roivant Sciences in a report on Thursday, May 21st. Leerink Partners set a $42.00 target price on Roivant Sciences in a research note on Thursday, May 21st. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Citigroup upped their price target on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. Finally, Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a report on Friday. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $33.59.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.